

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

Partnership with inQB8

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company has partnered with inQB8 Medical Technologies, LLC (“**inQB8**”), a US-based medical technology incubator, to explore innovative solutions for treating structural heart disease. The partnership includes the Company’s acquisition of a transcatheter tricuspid valve replacement (“**TTVR**”) technology from inQB8, which is currently in the animal studies stage, and for which inQB8 will continue with device development in partnership with the Company.

The arrangement constitutes a 50-50 ownership of the incubator between the Company and inQB8. Under the partnership, in the joint development of novel products and solutions in the structural heart field, the Company will have exclusive privileges and rights to these technologies globally.

The Board believes that this partnership with inQB8 will further expand the Company's product portfolio in transcatheter heart valves, and is another step for the Company to reach its goal of becoming a leading global player in the field.

As all applicable percentage ratios under Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") in relation to the transaction are respectively less than 5%, the transaction does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, June 10, 2021

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wayne Wu and Mr. Wai Ming Yip as independent non-executive Directors.